Add BrightSurf on Google Email

Science News for June 9, 2019


New research on diet and supplements during pregnancy and beyond

Studies found many prenatal supplements contain too much folic acid and often have higher nutrient content than labeled, while vitamin D supplementation improves babies' growth. A healthier diet before pregnancy may lower the risk of preeclampsia, and obesity severity affects weight gain and baby size during pregnancy

SourceAmerican Society for Nutrition·DateJun 9, 2019
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Study links poor sleep with poor nutrition

A new study found that people who get less than 7 hours of sleep per night tend to consume fewer essential vitamins and minerals. The research also revealed a greater association between poor sleep and lower nutrient intake in women.

SourceAmerican Society for Nutrition·DateJun 9, 2019

Sun-exposed oyster mushrooms help patients fight tuberculosis

Researchers found that sun-exposed oyster mushrooms can increase vitamin D levels and improve immunological responses in TB patients. The study used bread containing the mushrooms, which showed significant improvements in patients' TB severity scores and reduced vitamin D deficiency.

SourceAmerican Society for Nutrition·DateJun 9, 2019

Do policies targeting sugary drinks pay off?

A study estimates that a national SSB tax could prevent around 17,000 new obesity-associated cancer cases and save $2.4 billion in lifetime medical costs. Health warnings on SSBs can also reduce purchases and consumption, with potential to reduce average body mass index by about 0.6 kg/m2 over 5 years.

SourceAmerican Society for Nutrition·DateJun 9, 2019
Apple iPad Pro 11-inch (M4)

Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.

Drug delays type 1 diabetes in people at high risk

Researchers found that an immunotherapy treatment, teplizumab, effectively delayed the progression to clinical type 1 diabetes in high-risk individuals. Participants who received teplizumab took longer to develop clinical disease, with a median time of 48 months compared to just over 24 months for those in the control group.

SourceNIH/National Institute of Diabetes and Digestive and Kidney Diseases·JournalNew England Journal of Medicine·DateJun 9, 2019

Combination medication helps patients with type 2 diabetes maintain blood sugar goals

A randomized clinical trial found that patients taking IDegLira achieved and maintained lower blood glucose levels for longer periods compared to those taking insulin only. The study showed improved outcomes without the need for additional therapy, reducing side effects often associated with insulin-only treatment.

SourceBrigham and Women's Hospital·JournalThe Lancet Diabetes & Endocrinology·DateJun 9, 2019

The Lancet journals: Papers at American Diabetes Association (ADA) 2019

Two new trials show oral semaglutide is more effective than subcutaneous liraglutide in treating type 2 diabetes, with the latest trial showing it's also safe for patients with moderate renal impairment. Another trial found that insulin degludec plus liraglutide is a durable therapy option for type 2 diabetes.

SourceThe Lancet·JournalThe Lancet·DateJun 9, 2019